Cowpea Mosaic Virus and Natural Killer Cell Agonism for In Situ Cancer Vaccination

Researchers determined whether a combination of Cowpea mosaic virus (CPMV) and anti-4-1BB monoclonal antibody agonist to stimulate tumor-resident and CPMV-recruited NK cells was an effective dual therapy approach to improve NK cell function and in situ cancer vaccination efficacy.